Roivant Sciences: $1.4 Billion in Insider Sales — All Four Exit to Zero Shares

Four insiders at Roivant Sciences (ROIV) have sold a combined $1.41 billion in stock — and every single one of them now holds zero shares. The biotech-focused "vant" platform company has seen its most prominent backers completely exit.

Daniel Gold: The $619 Million Exit

Hedge fund manager Daniel Allen Gold leads the group with a staggering $619.4 million in career sales across 228 transactions. His recent selling wave of $149.8 million brought his holdings to zero. Gold, who manages QVT Financial, was one of Roivant's earliest and largest backers — and has now fully monetized that bet.

QVT Financial: $578 Million

QVT Financial LP, Gold's investment vehicle, separately recorded $578.5 million in sales across 209 transactions. The recent $126.9 million in sales completed the fund's exit. Between Gold's personal account and QVT, the combined exit exceeds $1.19 billion from a single investment thesis.

The Complete Exit

Insider / Entity	Career Sales	Transactions	Recent Sales	Shares After
Daniel Allen Gold	$619.4M	228	$149.8M	0
QVT Financial LP	$578.5M	209	$126.9M	0
Keith S. Manchester	$169.6M	57	$103.9M	0
Mayukh Sukhatme	$45.1M	43	$45.1M	0

Keith Manchester: $170 Million

Keith S. Manchester has sold $169.6 million across 57 transactions, with a massive $103.9 million in recent sales clearing his entire position. Manchester has been deeply involved with Roivant's "vant" model — the strategy of launching multiple subsidiary biotech companies under a shared platform.

President Exits With $45 Million

President and CIO Mayukh Sukhatme rounds out the quartet with $45.1 million in career sales across 43 transactions — notably, all of it in recent sales, suggesting a rapid, concentrated exit rather than gradual diversification. Like the others, Sukhatme holds zero shares.

What $1.4 Billion in Exits Means

Roivant's market cap is approximately $10 billion. The $1.41 billion in insider sales represents roughly 14% of the company's entire current value being extracted by just four insiders. With the company's highest-conviction backers completely exited, the ownership structure has fundamentally shifted.

The Roivant model — incubating subsidiary biotechs like Dermavant, Immunovant, and Proteovant — requires long-term capital commitment. The complete exit of its most prominent insiders raises questions about whether the remaining portfolio of "vants" justifies current valuations.

View all Roivant insider activity at ROIV stock page.